Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab-Reference-Cited by-同舟云学术

Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab

Published:2014-01-22 Issue:11 Volume:64 Page:569-575
ISSN:2194-9379
Container-title:Drug Research
language:en
Short-container-title:Drug Res (Stuttg)

Author:

Bittner B.¹,Richter W.²,Hourcade-Potelleret F.³,Herting F.⁴,Schmidt J.¹

Affiliation:

1. F. Hoffmann-La Roche Ltd., Product Optimization, Basel, Switzerland

2. F. Hoffmann-La Roche Ltd., Non-clinical Safety, Basel, Switzerland

3. F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland

4. Roche Diagnostics GmbH, Penzberg, Germany

Publisher

Georg Thieme Verlag KG

Subject

Drug Discovery,General Medicine

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0033-1363993.pdf

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access;BioDrugs;2023-10-13

2. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis;Journal of Oncology Pharmacy Practice;2023-06-16

3. Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review;Clinical Pharmacology & Therapeutics;2023-01-09

4. Mechanistic Modeling of the Effect of Recombinant Human Hyaluronidase (rHuPH20) on Subcutaneous Delivery of Cetuximab in Rats;Pharmaceutical Research;2022-07-01

5. Formulation and device lifecycle management of biotherapeutics—leveraging synergies across therapeutic areas;Formulation and Device Lifecycle Management of Biotherapeutics;2022